Market Overview

NeoStem's Progenitor Cell Therapy Announces Services Agreement with Sentien

Related NBS
Morning Market Losers
NeoStem Data From Phase 2 PreSERVE AMI Clinical Trial To Be Presented At American Heart Association Scientific Sessions On 11/17

NeoStem, Inc. (NYSE: NBS) and its subsidiary, Progenitor Cell Therapy LLC ("PCT"), announced today the execution of a Services Agreement with Sentien Biotechnologies, Inc. ("Sentien") under which PCT will provide services to support Sentien's development of its cell therapy product, including technology transfer, staff training, and manufacturing.

Sentien is developing an allogeneic cell therapy product consisting of bone marrow derived mesenchymal stem cells seeded onto a medical device for critical care indications. Sentien has engaged PCT for manufacture of the final formulation of its cell therapy product and intends to transfer and implement Sentien's master cell bank, product working cell bank and product manufacturing processes to PCT. These cell banks will be prepared according to Good Manufacturing Practices ("GMP") guidelines and implemented by PCT to create a cell therapy product for Sentien's Investigational New Drug ("IND") submission to the FDA. Upon obtaining an IND, Sentien intends to have PCT manufacture GMP compliant grade materials to support Sentien's Phase I clinical trial. 

Posted-In: News Contracts

 

Related Articles (NBS)

Around the Web, We're Loving...

Get Benzinga's Newsletters